Additional trials are needed to determine whether any of the biomarkers studied here is predictive of response to VEGF pathway targeting therapies, and when discordant tumor shrinkage is observed, whether it can be explained by differences in biomarker expression in primary and metastatic samples. The gene discussed is VEGFA; the disease is neoplasm.